Novartis gets US priority review voucher with Coartem approval
This article was originally published in Scrip
Executive Summary
The US FDA has approved Novartis's combination antimalarial Coartem (artemether plus lumefantrine), awarding the Swiss company the first priority review voucher under a new programme to spur development of tropical disease medicines.